title: Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
abstract: The aim of this review is to analyze the efficacy of different dopamine agonists in the prevention of ovarian hyperstimulation syndrome (OHSS). Cabergoline, quinagolide and bromocriptine are the most common dopamine agonists used. There are wide clinical variations among the trials in the starting time (from the day of human chorionic gonadotrophin (hCG) to the day following oocyte retrieval); the duration of the treatment (4-21 days), the dose of cabergoline (0.5 mg or 0.25 mg orally) and in the regimens used. At present, the best known effective regimen is 0.5 mg of cabergoline for 8 days or rectal bromocriptine at a daily dose of 2.5 mg for 16 days. Dopamine agonists have shown significant evidences of their efficacy in the prevention of moderate and early-onset OHSS (9.41%), compared with a placebo (21.45%), which cannot be confirmed for the treatment of late OHSS. It would be advisable to start with the treatment on the day of hCG injection or preferably a few hours earlier. The use of dopamine agonists should be indicated in patients at high risk of OHSS, as well as in patients with a history of previous OHSS even without evident signs of the syndrome.
authors.affiliation: a Department of Obstetrics and Gynaecology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Miro
authors.initials: M
authors.lastname: Kasum
authors.affiliation: a Department of Obstetrics and Gynaecology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Hrvoje
authors.initials: H
authors.lastname: Vrčić
authors.affiliation: a Department of Obstetrics and Gynaecology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Patrik
authors.initials: P
authors.lastname: Stanić
authors.affiliation: b Department of Histology and Embryology, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Davor
authors.initials: D
authors.lastname: Ježek
authors.affiliation: a Department of Obstetrics and Gynaecology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Slavko
authors.initials: S
authors.lastname: Orešković
authors.affiliation: c Department of Oncology, Clinical Hospital Centre Sisters of Mercy, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Lidija
authors.initials: L
authors.lastname: Beketić-Orešković
authors.affiliation: a Department of Obstetrics and Gynaecology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb Zagreb Croatia.
authors.forename: Marijeta
authors.initials: M
authors.lastname: Pekez
mesh_terms: D000634:Aminoquinolines / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects*
chemical_list: D000634:Aminoquinolines; D018491:Dopamine Agonists; D004873:Ergolines; D001971:Bromocriptine; C046650:quinagolide; D000077465:Cabergoline
keywords: Dopamine agonist; ovarian hyperstimulation syndrome; prevention